List of Excipients in Branded Drug DALBAVANCIN HYDROCHLORIDE

« Back to Dashboard

Generic Drugs Containing DALBAVANCIN HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Fresenius Kabi USA LLC	dalbavancin hydrochloride	65219-120	HYDROCHLORIC ACID
Fresenius Kabi USA LLC	dalbavancin hydrochloride	65219-120	LACTOSE MONOHYDRATE
Fresenius Kabi USA LLC	dalbavancin hydrochloride	65219-120	MANNITOL
Fresenius Kabi USA LLC	dalbavancin hydrochloride	65219-120	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in DALBAVANCIN HYDROCHLORIDE?

# Of NDCs	Excipient
1	HYDROCHLORIC ACID
1	LACTOSE MONOHYDRATE
1	MANNITOL
1	SODIUM HYDROXIDE

Dalbavancin Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: October 14, 2026

Dalbavancin hydrochloride is a long-acting lipoglycopeptide antibiotic supplied as a sterile, single-dose lyophilized powder for intravenous infusion. The U.S. commercial formulation uses mannitol and lactose monohydrate as the principal excipients. The most credible commercial opportunities are in formulation simplification, outpatient administration, supply-chain resilience, sterile packaging, and alternative delivery formats rather than in cosmetic excipient substitution alone (FDA, 2024a).

What excipients are used in dalbavancin hydrochloride products?

The U.S. DALVANCE formulation contains dalbavancin hydrochloride equivalent to 500 mg of dalbavancin, 750 mg of mannitol, and 50 mg of lactose monohydrate per vial. The product is reconstituted with Sterile Water for Injection and diluted in 5% Dextrose Injection before intravenous administration (FDA, 2024a).

Component	Function	Commercial relevance
Dalbavancin hydrochloride	Active pharmaceutical ingredient	Complex glycopeptide with high molecular weight and impurity-control requirements
Mannitol, 750 mg/vial	Bulking agent and lyophilization aid	Supports cake structure, dose uniformity, and reconstitution performance
Lactose monohydrate, 50 mg/vial	Stabilizer and formulation modifier	May support solid-state stability and product performance
Hydrochloric acid or sodium hydroxide	pH adjustment during manufacture	Controls solution stability before lyophilization
Sterile Water for Injection	Reconstitution diluent	Required for preparation of the injectable solution
5% Dextrose Injection	Final dilution vehicle	The labeled dilution vehicle in the U.S. product

European product information also identifies mannitol and lactose monohydrate in the 500 mg vial formulation (EMA, 2024).

Why mannitol is strategically important

Mannitol is more than an inert filler in this product. It contributes to the physical structure of the lyophilized cake and affects:

• Primary drying behavior
• Collapse temperature
• Residual moisture
• Reconstitution time
• Cake appearance
• Container-to-container dose consistency
• Long-term storage stability

A change in mannitol grade, particle-size distribution, bioburden, endotoxin profile, or supplier can affect the lyophilization cycle and finished-product attributes. Pharmaceutical-grade mannitol with consistent thermal and particulate specifications is therefore a supply-chain opportunity.

Potential suppliers can differentiate through low-endotoxin grades, improved lot-to-lot control, regional manufacturing, and validated supply continuity rather than through a new chemical identity.

Why lactose monohydrate is strategically important

Lactose monohydrate is present at a lower concentration than mannitol but can affect the solid-state environment of the active ingredient. Its commercial value lies in maintaining a tightly controlled excipient profile and avoiding variability in:

• Moisture content
• Reducing-sugar impurities
• Particle morphology
• Residual proteins or processing contaminants
• Sterility and endotoxin control
• Interaction with the glycopeptide during storage

Lactose-free reformulation could be commercially attractive for selected patient populations, but any substitution would require comparative stability, reconstitution, potency, degradation, particulate, and clinical-use assessments.

What formulation characteristics must an excipient strategy preserve?

The central formulation target is a stable sterile lyophilized cake that rapidly produces a clear or essentially particle-free solution after reconstitution and dilution.

Critical quality attributes include:

Quality attribute	Excipient impact
Assay and related substances	Moisture, pH, oxygen exposure, and solid-state interactions
Reconstitution time	Cake porosity, residual moisture, vial fill, and diluent volume
Visible and subvisible particles	Excipient purity, stopper interaction, and handling
pH	Acid/base adjustment and diluent compatibility
Osmolality	Total solids and final infusion volume
Color and appearance	Degradation and cake collapse
Sterility and endotoxin	Raw-material controls and aseptic processing
Stability after reconstitution	Temperature, time, container, and infusion vehicle

Dalbavancin is administered intravenously, so excipient selection is constrained by parenteral safety, particulate limits, compatibility with infusion equipment, and container-closure performance. Oral excipient strategies have limited relevance unless a new delivery route is developed.

What formulations are protected by dalbavancin patents?

Dalbavancin intellectual property has historically covered the active glycopeptide, derivatives, pharmaceutical compositions, manufacturing processes, and therapeutic uses. The commercial formulation may also be affected by patents covering:

• Lyophilized dalbavancin compositions
• Excipient ratios
• Stabilized aqueous solutions
• Reconstitution and dilution methods
• Treatment of acute bacterial skin and skin-structure infections
• Extended-interval dosing
• Manufacturing and purification processes
• Specific impurity limits or solid-state characteristics

The practical freedom-to-operate question is narrower than whether a formulation is chemically different. A generic or reformulator must assess whether its product falls within claims covering the same active ingredient, dosage form, excipient combination, process, or labeled indication.

Excipient substitution does not automatically avoid infringement. A patent claim covering a dalbavancin composition may be drafted broadly enough to capture multiple bulking agents or stabilizers. Conversely, a narrow claim limited to a specific excipient ratio may be avoided with a properly characterized alternative.

When does dalbavancin lose exclusivity?

Dalbavancin’s principal U.S. regulatory exclusivity periods have expired. DALVANCE received U.S. approval in 2014 for acute bacterial skin and skin-structure infections, and the product has been marketed for extended-interval intravenous treatment (FDA, 2014; FDA, 2024a).

Regulatory exclusivity and patent exclusivity must be separated:

Exclusivity category	Dalbavancin position
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not the primary commercial protection for the approved indication
Pediatric exclusivity	No material current barrier identified from the commercial label
Patent exclusivity	Must be assessed by jurisdiction, claim scope, and current Orange Book listings
Data exclusivity	Historical approval-period protection has expired
Biosimilar exclusivity	Not applicable to this small-molecule antibiotic

The commercial exposure is therefore primarily a patent, manufacturing, regulatory, and market-access question rather than a remaining NCE exclusivity question.

What is the Orange Book status of dalbavancin?

Dalbavancin hydrochloride is a small-molecule drug and may be subject to an abbreviated new drug application under the ANDA pathway. The Orange Book is the controlling source for current listed patents, expiry dates, use codes, and therapeutic-equivalence information (FDA, 2024b).

Orange Book analysis should focus on:

1. The listed reference product and dosage form.
2. Any active ingredient, formulation, or method-of-use patents.
3. Patent expiry dates and pediatric extensions.
4. Whether a listed patent is subject to a Paragraph IV certification.
5. Whether the applicant seeks approval for all labeled uses or omits protected indications under a section viii statement.
6. Whether the reference product has been designated as a discontinued product or remains commercially active.

The key commercial point is that an ANDA applicant does not necessarily need to reproduce every branded excipient. It must demonstrate pharmaceutical equivalence and bioequivalence or satisfy the applicable injectable-product requirements. For a parenteral solution or lyophilized injectable, the FDA evaluates formulation, route, strength, quality, sterility, and other product-specific criteria.

Which companies are challenging dalbavancin?

Publicly visible commercial competition has historically been limited compared with older hospital antibiotics. Dalbavancin is a complex injectable glycopeptide with a relatively concentrated market and high manufacturing requirements.

Potential challengers fall into four groups:

Challenger type	Likely strategy
ANDA generic manufacturer	Reproduce the 500 mg lyophilized vial and challenge or wait out listed patents
Injectable CDMO	Manufacture for a generic sponsor or support an authorized alternative
Hospital antibiotic company	Compete through contracting, stewardship, and outpatient-care positioning
Drug-delivery company	Develop ready-to-use, premixed, or reduced-preparation presentations

The principal economic barrier is not simply active-ingredient synthesis. It includes sterile manufacturing, lyophilization capacity, analytical characterization, impurity control, vial filling, stability data, and regulatory validation.

What Paragraph IV risks exist for dalbavancin?

A Paragraph IV applicant would assert that a listed patent is invalid, unenforceable, or not infringed. The most plausible technical arguments would involve:

• Non-infringement through an alternative excipient system
• Different excipient ratios
• A different lyophilization process
• A different vial or stopper configuration
• A section viii carve-out for a protected method of use
• Invalidity based on anticipation or obviousness
• Lack of written description or enablement for broad formulation claims

The strongest defense for the patent holder would generally involve narrow, experimentally supported formulation claims tied to a measurable stability or reconstitution advantage. Broad claims directed only to the presence of dalbavancin plus a conventional bulking agent may face greater invalidity or design-around pressure.

No conclusion about a current Paragraph IV challenge should be drawn without reviewing the latest FDA Orange Book, ANDA litigation filings, and district court docket records.

What generic launch scenarios exist?

Scenario 1: Same-formulation generic

A sponsor reproduces the 500 mg vial with mannitol and lactose monohydrate. This approach minimizes formulation risk but may increase exposure to composition, process, or formulation patents.

Scenario 2: Alternative-excipient generic

A sponsor replaces lactose, mannitol, or both. This may create a design-around position but increases development risk. The sponsor must establish equivalent performance in lyophilization, reconstitution, stability, sterility, and administration.

Scenario 3: Restricted-label launch

A sponsor omits a patented use while pursuing approval for an unprotected indication. This strategy depends on the scope of listed method-of-use patents and whether the omitted use is operationally separable in prescribing and promotion.

Scenario 4: Authorized generic or licensed product

The originator or marketing partner licenses supply to another company. This can reduce litigation risk but may compress price and expand hospital-account coverage.

Scenario 5: Reformulated 505(b)(2) product

A new presentation could pursue reduced preparation time, extended in-use stability, or a new delivery system. The commercial value must justify a higher regulatory and clinical burden than a conventional ANDA.

What commercial opportunities exist for excipient and packaging suppliers?

Ready-to-use or dual-chamber presentation

The current preparation process requires reconstitution and dilution. A dual-chamber vial, dual-chamber bag, or premixed infusion could reduce pharmacy labor and medication-preparation errors. The main barriers are stability in the liquid state, container compatibility, oxygen exposure, particulate control, and transport conditions.

Improved lyophilization excipients

Potential development areas include:

• Alternative sugar or polyol systems
• Mannitol combinations with controlled crystallinity
• Non-lactose stabilizers
• Lower-moisture cake systems
• Faster-reconstitution formulations
• Excipient systems that tolerate wider temperature excursions

The best opportunity is an excipient system that reduces cycle time or improves shelf life without changing the clinical dose or administration route.

Container-closure systems

High-value components include:

• Low-extractable elastomeric stoppers
• Improved seal integrity
• Ready-to-reconstitute vial systems
• Reduced-sorption materials
• Tamper-evident hospital packaging
• Larger multipack configurations for outpatient infusion centers

Outpatient and home-infusion products

Dalbavancin’s extended dosing schedule supports outpatient treatment and can reduce hospital resource use. Products that simplify preparation, limit nursing time, and improve cold-chain flexibility may command commercial value even without changing the active ingredient (Boucher et al., 2014).

How strong is the dalbavancin formulation opportunity?

The opportunity is technically meaningful but commercially selective.

Factor	Assessment
Excipient substitution potential	Moderate
Lyophilized injectable complexity	High
Need for clinical reformulation	Low for equivalent ANDA; higher for new delivery systems
Manufacturing barrier	High
Patent design-around potential	Moderate, claim-dependent
Hospital value of preparation simplification	High
Biosimilar opportunity	Not applicable
Conventional generic opportunity	Possible but technically demanding
Premium reformulation opportunity	Strongest in outpatient and home infusion

The most defensible commercial positions are likely to involve integrated CMC and delivery-system improvements, not a simple replacement of lactose or mannitol.

What litigation and licensing issues affect dalbavancin?

Litigation risk can arise from four areas:

1. Patent infringement involving the active ingredient or formulation.
2. ANDA litigation triggered by a Paragraph IV certification.
3. Contract disputes involving manufacturing, supply, or distribution.
4. Regulatory disputes over equivalence, labeling, or approval timing.

Licensing opportunities are most credible for regional commercialization, generic supply, hospital distribution, and CDMO manufacturing. A license that transfers only commercial rights without validated sterile manufacturing capacity would not remove the principal technical barriers.

Publicly reported commercial arrangements should be reviewed against the relevant product owner, marketing authorization holder, and manufacturing entity because ownership and commercialization rights can differ across the United States, European Union, and other jurisdictions.

Key Takeaways

• Dalbavancin hydrochloride is marketed as a sterile lyophilized intravenous product.
• The U.S. DALVANCE formulation contains mannitol and lactose monohydrate.
• Mannitol primarily supports cake structure and lyophilization performance; lactose contributes to formulation stability.
• The strongest commercial opportunities are improved reconstitution, ready-to-use delivery, outpatient packaging, sterile supply resilience, and alternative formulations.
• Dalbavancin is not eligible for a biosimilar pathway because it is a small-molecule antibiotic.
• Generic entry is technically possible but constrained by sterile injectable manufacturing, lyophilization, analytical characterization, and patent risk.
• Excipient substitution may support a design-around strategy but does not automatically avoid formulation or process claims.
• Current patent and Paragraph IV conclusions require product-specific review of the latest Orange Book and litigation records.

FAQs

Can lactose be removed from a dalbavancin formulation?

Yes, technically, but removal would require a new formulation-development program addressing stability, reconstitution, particulate matter, sterility, potency, and regulatory equivalence.

Is dalbavancin suitable for a premixed infusion bag?

Potentially, but liquid-state stability is a major barrier. A premixed product would require validated compatibility with the bag, tubing, diluent, stopper or port system, and intended storage conditions.

Does changing mannitol grade create a new pharmaceutical product?

Not necessarily. A supplier or grade change may be handled as a manufacturing change if comparability is demonstrated. A material change in function, composition, or performance can require a more extensive regulatory submission.

Can a generic dalbavancin product use different excipients?

Yes, subject to applicable FDA requirements for injectable products and demonstration that the formulation meets pharmaceutical-equivalence, quality, stability, and safety standards.

What is the most attractive commercial reformulation?

A validated ready-to-use or reduced-preparation presentation is likely more commercially attractive than a minor excipient substitution because it can reduce pharmacy labor, preparation time, and administration complexity.

References

Boucher, H. W., Wilcox, M., Talbot, G. H., Puttagunta, S., Das, A. F., & Dunne, M. W. (2014). Once-weekly dalbavancin versus daily conventional therapy for skin infection. New England Journal of Medicine, 370(23), 2169-2179.

European Medicines Agency. (2024). Xydalba: European public assessment report and product information. https://www.ema.europa.eu/

U.S. Food and Drug Administration. (2014). FDA approves new antibacterial drug Dalvance to treat skin infections. https://www.fda.gov/

U.S. Food and Drug Administration. (2024a). DALVANCE (dalbavancin hydrochloride) for injection: Prescribing information. https://www.accessdata.fda.gov/

U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/-drugs/abbreviated-new-drug-application-anda/orange-book-data-files